Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study: Multiple sclerosis (Houndmills, Basingstoke, England)

D Baroncini; M Zaffaroni; L Moiola; L Lorefice; G Fenu; P Iaffaldano; M Simone; F Fanelli; F Patti; E D'Amico; M Capobianco; A Bertolotto; P Gallo; M Margoni; S Miante; N Milani; MP Amato; I Righini; P Bellantonio; C Scandellari; G Costantino; E Scarpini; R Bergamaschi; G Mallucci; G Comi; A Ghezzi; on behalf of the iMED Registry; Gruppo di Studio SM-Società Italiana di Neurologia

doi:10.1177/1352458518754364

Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study: Multiple sclerosis (Houndmills, Basingstoke, England)

D Baroncini, M Zaffaroni, L Moiola, L Lorefice, G Fenu, P Iaffaldano, M Simone, F Fanelli, F Patti, E D'Amico, M Capobianco, A Bertolotto, P Gallo, M Margoni, S Miante, N Milani, MP Amato, I Righini, P Bellantonio, C ScandellariG Costantino, E Scarpini, R Bergamaschi, G Mallucci, G Comi, A Ghezzi, on behalf of the iMED Registry, Gruppo di Studio SM-Società Italiana di Neurologia

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: Few data are available on very long-term follow-up of pediatric multiple sclerosis (MS) patients treated with disease modifying treatments (DMTs). OBJECTIVES: To present a long-term follow-up of a cohort of Pediatric-MS patients starting injectable first-line agents. METHODS: Data regarding treatments, annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS) score, and serious adverse event were collected. Baseline characteristics were tested in multivariate analysis to identify predictors of disease evolution. RESULTS: In total, 97 patients were followed for 12.5 ± 3.3 years. They started therapy at 13.9 ± 2.1 years, 88 with interferons and 9 with copaxone. During the whole follow-up, 82 patients changed therapy, switching to immunosuppressors/second-line treatment in 58% of cases. Compared to pre-treatment phase, the ARR was significantly reduced during the first treatment (from 3.2 ± 2.6 to 0.7 ± 1.5, p

Original language	English
Pages (from-to)	399-407
Number of pages	9
Journal	Multiple Sclerosis
Volume	25
Issue number	3
DOIs	https://doi.org/10.1177/1352458518754364
Publication status	Published - 2019

Access to Document

10.1177/1352458518754364

http://www.scopus.com/inward/record.url?scp=85043324010&partnerID=8YFLogxK

Fingerprint

Dive into the research topics of 'Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study: Multiple sclerosis (Houndmills, Basingstoke, England)'. Together they form a unique fingerprint.

Cite this

Baroncini, D., Zaffaroni, M., Moiola, L., Lorefice, L., Fenu, G., Iaffaldano, P., Simone, M., Fanelli, F., Patti, F., D'Amico, E., Capobianco, M., Bertolotto, A., Gallo, P., Margoni, M., Miante, S., Milani, N., Amato, MP., Righini, I., Bellantonio, P., ... Neurologia, G. D. S. SM-S. I. D. (2019). Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study: Multiple sclerosis (Houndmills, Basingstoke, England). Multiple Sclerosis, 25(3), 399-407. https://doi.org/10.1177/1352458518754364

Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study : Multiple sclerosis (Houndmills, Basingstoke, England). / Baroncini, D; Zaffaroni, M; Moiola, L; Lorefice, L; Fenu, G; Iaffaldano, P; Simone, M; Fanelli, F; Patti, F; D'Amico, E; Capobianco, M; Bertolotto, A; Gallo, P; Margoni, M; Miante, S; Milani, N; Amato, MP; Righini, I; Bellantonio, P; Scandellari, C; Costantino, G; Scarpini, E; Bergamaschi, R; Mallucci, G; Comi, G; Ghezzi, A; Registry, on behalf of the iMED; Neurologia, Gruppo di Studio SM-Società Italiana di.

In: Multiple Sclerosis, Vol. 25, No. 3, 2019, p. 399-407.

Research output: Contribution to journal › Article › peer-review

Baroncini, D, Zaffaroni, M, Moiola, L, Lorefice, L, Fenu, G, Iaffaldano, P, Simone, M, Fanelli, F, Patti, F, D'Amico, E, Capobianco, M, Bertolotto, A, Gallo, P, Margoni, M, Miante, S, Milani, N, Amato, MP, Righini, I, Bellantonio, P, Scandellari, C, Costantino, G, Scarpini, E, Bergamaschi, R, Mallucci, G, Comi, G, Ghezzi, A, Registry, OBOTIMED & Neurologia, GDSSM-SID 2019, 'Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study: Multiple sclerosis (Houndmills, Basingstoke, England)', Multiple Sclerosis, vol. 25, no. 3, pp. 399-407. https://doi.org/10.1177/1352458518754364

Baroncini D, Zaffaroni M, Moiola L, Lorefice L, Fenu G, Iaffaldano P et al. Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study: Multiple sclerosis (Houndmills, Basingstoke, England). Multiple Sclerosis. 2019;25(3):399-407. https://doi.org/10.1177/1352458518754364

Baroncini, D ; Zaffaroni, M ; Moiola, L ; Lorefice, L ; Fenu, G ; Iaffaldano, P ; Simone, M ; Fanelli, F ; Patti, F ; D'Amico, E ; Capobianco, M ; Bertolotto, A ; Gallo, P ; Margoni, M ; Miante, S ; Milani, N ; Amato, MP ; Righini, I ; Bellantonio, P ; Scandellari, C ; Costantino, G ; Scarpini, E ; Bergamaschi, R ; Mallucci, G ; Comi, G ; Ghezzi, A ; Registry, on behalf of the iMED ; Neurologia, Gruppo di Studio SM-Società Italiana di. / Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study : Multiple sclerosis (Houndmills, Basingstoke, England). In: Multiple Sclerosis. 2019 ; Vol. 25, No. 3. pp. 399-407.

@article{5599188b845d46428066b1980a081843,

title = "Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study: Multiple sclerosis (Houndmills, Basingstoke, England)",

abstract = "BACKGROUND: Few data are available on very long-term follow-up of pediatric multiple sclerosis (MS) patients treated with disease modifying treatments (DMTs). OBJECTIVES: To present a long-term follow-up of a cohort of Pediatric-MS patients starting injectable first-line agents. METHODS: Data regarding treatments, annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS) score, and serious adverse event were collected. Baseline characteristics were tested in multivariate analysis to identify predictors of disease evolution. RESULTS: In total, 97 patients were followed for 12.5 ± 3.3 years. They started therapy at 13.9 ± 2.1 years, 88 with interferons and 9 with copaxone. During the whole follow-up, 82 patients changed therapy, switching to immunosuppressors/second-line treatment in 58% of cases. Compared to pre-treatment phase, the ARR was significantly reduced during the first treatment (from 3.2 ± 2.6 to 0.7 ± 1.5, p ",

author = "D Baroncini and M Zaffaroni and L Moiola and L Lorefice and G Fenu and P Iaffaldano and M Simone and F Fanelli and F Patti and E D'Amico and M Capobianco and A Bertolotto and P Gallo and M Margoni and S Miante and N Milani and MP Amato and I Righini and P Bellantonio and C Scandellari and G Costantino and E Scarpini and R Bergamaschi and G Mallucci and G Comi and A Ghezzi and Registry, {on behalf of the iMED} and Neurologia, {Gruppo di Studio SM-Societ{\`a} Italiana di}",

year = "2019",

doi = "10.1177/1352458518754364",

language = "English",

volume = "25",

pages = "399--407",

journal = "Multiple Sclerosis",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "3",

}

TY - JOUR

T1 - Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study

T2 - Multiple sclerosis (Houndmills, Basingstoke, England)

AU - Baroncini, D

AU - Zaffaroni, M

AU - Moiola, L

AU - Lorefice, L

AU - Fenu, G

AU - Iaffaldano, P

AU - Simone, M

AU - Fanelli, F

AU - Patti, F

AU - D'Amico, E

AU - Capobianco, M

AU - Bertolotto, A

AU - Gallo, P

AU - Margoni, M

AU - Miante, S

AU - Milani, N

AU - Amato, MP

AU - Righini, I

AU - Bellantonio, P

AU - Scandellari, C

AU - Costantino, G

AU - Scarpini, E

AU - Bergamaschi, R

AU - Mallucci, G

AU - Comi, G

AU - Ghezzi, A

AU - Registry, on behalf of the iMED

AU - Neurologia, Gruppo di Studio SM-Società Italiana di

PY - 2019

Y1 - 2019

N2 - BACKGROUND: Few data are available on very long-term follow-up of pediatric multiple sclerosis (MS) patients treated with disease modifying treatments (DMTs). OBJECTIVES: To present a long-term follow-up of a cohort of Pediatric-MS patients starting injectable first-line agents. METHODS: Data regarding treatments, annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS) score, and serious adverse event were collected. Baseline characteristics were tested in multivariate analysis to identify predictors of disease evolution. RESULTS: In total, 97 patients were followed for 12.5 ± 3.3 years. They started therapy at 13.9 ± 2.1 years, 88 with interferons and 9 with copaxone. During the whole follow-up, 82 patients changed therapy, switching to immunosuppressors/second-line treatment in 58% of cases. Compared to pre-treatment phase, the ARR was significantly reduced during the first treatment (from 3.2 ± 2.6 to 0.7 ± 1.5, p

AB - BACKGROUND: Few data are available on very long-term follow-up of pediatric multiple sclerosis (MS) patients treated with disease modifying treatments (DMTs). OBJECTIVES: To present a long-term follow-up of a cohort of Pediatric-MS patients starting injectable first-line agents. METHODS: Data regarding treatments, annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS) score, and serious adverse event were collected. Baseline characteristics were tested in multivariate analysis to identify predictors of disease evolution. RESULTS: In total, 97 patients were followed for 12.5 ± 3.3 years. They started therapy at 13.9 ± 2.1 years, 88 with interferons and 9 with copaxone. During the whole follow-up, 82 patients changed therapy, switching to immunosuppressors/second-line treatment in 58% of cases. Compared to pre-treatment phase, the ARR was significantly reduced during the first treatment (from 3.2 ± 2.6 to 0.7 ± 1.5, p

U2 - 10.1177/1352458518754364

DO - 10.1177/1352458518754364

M3 - Article

VL - 25

SP - 399

EP - 407

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 3

ER -